Drug
Orelabrutinib High Dose
Orelabrutinib High Dose: highest development phase Phase 2, developed by InnoCare Pharma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- InnoCare Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| Orelabrutinib High dose NCT05978739 | Phase 2 | Mantle Cell Lymphoma |
Latest
No recent events.
Follow Orelabrutinib High Dose on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.